JP5524130B2 - Stabilized vitamin preparation - Google Patents
Stabilized vitamin preparation Download PDFInfo
- Publication number
- JP5524130B2 JP5524130B2 JP2011112646A JP2011112646A JP5524130B2 JP 5524130 B2 JP5524130 B2 JP 5524130B2 JP 2011112646 A JP2011112646 A JP 2011112646A JP 2011112646 A JP2011112646 A JP 2011112646A JP 5524130 B2 JP5524130 B2 JP 5524130B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- starch
- calcium
- carmellose
- calcium pantothenate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 22
- 229940088594 vitamin Drugs 0.000 title description 10
- 229930003231 vitamin Natural products 0.000 title description 10
- 235000013343 vitamin Nutrition 0.000 title description 10
- 239000011782 vitamin Substances 0.000 title description 10
- 150000003722 vitamin derivatives Chemical class 0.000 title description 9
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 47
- 229960002079 calcium pantothenate Drugs 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 29
- -1 vitamin B 12 compound Chemical class 0.000 claims description 24
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 23
- 239000001913 cellulose Substances 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 19
- 229920002678 cellulose Polymers 0.000 claims description 18
- 235000010980 cellulose Nutrition 0.000 claims description 18
- 229950006836 fursultiamine Drugs 0.000 claims description 17
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000006185 dispersion Substances 0.000 claims description 10
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 8
- 239000001527 calcium lactate Substances 0.000 claims description 8
- 229960002401 calcium lactate Drugs 0.000 claims description 8
- 235000011086 calcium lactate Nutrition 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 229950008138 carmellose Drugs 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000000626 magnesium lactate Substances 0.000 claims description 7
- 229960004658 magnesium lactate Drugs 0.000 claims description 7
- 235000015229 magnesium lactate Nutrition 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229960005069 calcium Drugs 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 229920001592 potato starch Polymers 0.000 claims description 4
- 229920003124 powdered cellulose Polymers 0.000 claims description 4
- 235000019814 powdered cellulose Nutrition 0.000 claims description 4
- 229940100486 rice starch Drugs 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 229940116317 potato starch Drugs 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims 2
- 235000021307 Triticum Nutrition 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 36
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 30
- 239000000843 powder Substances 0.000 description 30
- 239000011248 coating agent Substances 0.000 description 21
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 20
- 238000000576 coating method Methods 0.000 description 19
- 239000008213 purified water Substances 0.000 description 19
- 235000000639 cyanocobalamin Nutrition 0.000 description 15
- 239000011666 cyanocobalamin Substances 0.000 description 15
- 229960002104 cyanocobalamin Drugs 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000008298 dragée Substances 0.000 description 11
- 239000007940 sugar coated tablet Substances 0.000 description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 9
- 239000004386 Erythritol Substances 0.000 description 9
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 9
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 9
- 235000019414 erythritol Nutrition 0.000 description 9
- 229940009714 erythritol Drugs 0.000 description 9
- 229960002477 riboflavin Drugs 0.000 description 9
- 235000019192 riboflavin Nutrition 0.000 description 9
- 239000002151 riboflavin Substances 0.000 description 9
- 239000000454 talc Substances 0.000 description 9
- 229910052623 talc Inorganic materials 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000011812 mixed powder Substances 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 244000215068 Acacia senegal Species 0.000 description 6
- 229920000084 Gum arabic Polymers 0.000 description 6
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 6
- 235000010489 acacia gum Nutrition 0.000 description 6
- 239000000205 acacia gum Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 6
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 6
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 6
- 238000004513 sizing Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000009495 sugar coating Methods 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000004203 carnauba wax Substances 0.000 description 3
- 235000013869 carnauba wax Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 3
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 239000011049 pearl Substances 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 2
- QEKBRBCVWVLFHH-QAKUKHITSA-L Tocopherol calcium succinate Chemical compound [Ca+2].[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C.[O-]C(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C QEKBRBCVWVLFHH-QAKUKHITSA-L 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960005010 orotic acid Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 229950001574 riboflavin phosphate Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- 241000490494 Arabis Species 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960005469 hydroxocobalamin acetate Drugs 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、塩酸フルスルチアミン、ビタミンB6類、ビタミンB12類およびパントテン酸カルシウムを含有する固形のビタミン製剤におけるパントテン酸カルシウムと、ビタミンB12類とを共に安定化することに関する。 The present invention, fursultiamine hydrochloride, vitamin B 6 such, and calcium pantothenate in the vitamin formulation of solids containing vitamin B 12 acids and calcium pantothenate, relates to both stabilize and vitamin B 12 compound.
パントテン酸カルシウムは、アスコルビン酸との配合性が悪く、安定性が低下することが知られている。また、水分にも不安定である。このため、アスコルビン酸またはその塩とパントテン酸カルシウムを含有する製剤では、パントテン酸カルシウム含有組成物を用い、かつ低水分化することで安定化する方法が知られている(特許文献1および2)。
一方、ビタミンB12類は、水分に不安定で、ビタミンB6類と配合すると不安定化することが知られ、ビタミンB12類の安定化方法がいくつか提案されている(特許文献3〜6)。
しかし、これらには、塩酸フルスルチアミンと、ビタミンB6類と、ビタミンB12類と、パントテン酸カルシウムとを配合し、低水分化された製剤におけるパントテン酸カルシウムとビタミンB12類の不安定化に関しては明らかにされておらず、解決法の開示も示唆もない。
On the other hand, vitamin B 12 is unstable to moisture and is known to be unstable when it is combined with vitamin B 6 and several methods for stabilizing vitamin B 12 have been proposed (Patent Documents 3 to 3). 6).
However, these are unstable and fursultiamine hydrochloride, vitamin B 6 such, and vitamin B 12 compound, blended with calcium pantothenate, low moisture reduction calcium pantothenate in the formulation and vitamin B 12 compound There is no clarification regarding the conversion, and there is no disclosure or suggestion of a solution.
本発明の目的は、塩酸フルスルチアミン、ビタミンB6類、ビタミンB12類およびパントテン酸カルシウムを含有する固形のビタミン製剤であって、パントテン酸カルシウムおよびビタミンB12類が共に安定化された固形製剤を提供することにある。 The solid object of the present invention, fursultiamine hydrochloride, vitamin B 6 such, a vitamin formulation solids containing vitamin B 12 acids and calcium pantothenate, calcium pantothenate and vitamin B 12 compounds are both stabilized It is to provide a formulation.
本発明者らは、上記の目的を達成するために鋭意検討した結果、塩酸フルスルチアミン、ビタミンB6類、ビタミンB12類およびパントテン酸カルシウムを含有する固形製剤において、パントテン酸カルシウム含有組成物を乾式で配合し、ビタミンB12類を水に溶解または分散した液をパントテン酸カルシウム以外の薬物および/または賦形剤に噴霧、乾燥して得られた粒で配合することにより、パントテン酸カルシウムと、ビタミンB12類が共に安定化できることを見出し、本発明を完成するに至った。 The present inventors have made intensive studies in order to achieve the above object, fursultiamine hydrochloride, vitamin B 6 such, in the solid preparation containing vitamin B 12 acids and calcium pantothenate, calcium pantothenate-containing composition By blending with a granule obtained by spraying and drying a solution obtained by dissolving or dispersing vitamin B 12 in water in a drug and / or excipient other than calcium pantothenate, If, it found that vitamin B 12 compound can both stabilize, and have completed the present invention.
すなわち、本発明は、
(1)塩酸フルスルチアミンと、ビタミンB6類と、ビタミンB12類と、パントテン酸カルシウムとを含有する固形製剤であって、パントテン酸カルシウムを、パントテン酸カルシウムと、それ自体が中性ないし塩基性のマグネシウムまたはカルシウムの乳酸塩または炭酸塩とを、水および/または低級アルコールの存在下に混合し、ついで該混合物を乾燥することにより得られる組成物として含有することを特徴とする固形製剤、
(2)ビタミンB12類を、その水溶液または水分散液をパントテン酸カルシウム以外の薬物および/または賦形剤に噴霧、乾燥して得られた粒として含有する上記(1)記載の固形製剤、
(3)コーティングされている上記(1)記載の固形製剤、
(4)パントテン酸カルシウムと、それ自体が中性ないし塩基性のマグネシウムまたはカルシウムの乳酸塩または炭酸塩とを、水および/または低級アルコールの存在下に混合し、ついで該混合物を乾燥することにより得られる組成物と、ビタミンB12類を、その水溶液または水分散液をパントテン酸カルシウム以外の薬物および/または賦形剤に噴霧、乾燥して得られた粒とを乾式で配合することを特徴とする上記(1)記載の固形製剤の製造方法、および
(5)パントテン酸カルシウムと、それ自体が中性ないし塩基性のマグネシウムまたはカルシウムの乳酸塩または炭酸塩とを、水および/または低級アルコールの存在下に混合し、ついで該混合物を乾燥することにより得られる組成物と、ビタミンB12類を、その水溶液または水分散液をパントテン酸カルシウム以外の薬物および/または賦形剤に噴霧、乾燥して得られた粒とを乾式で配合することを特徴とする塩酸フルスルチアミンと、ビタミンB6類と、ビタミンB12類と、パントテン酸カルシウムとを含有する固形製剤におけるビタミンB12類とパントテン酸カルシウムの両方を安定化させる方法を提供するものである。
That is, the present invention
(1) and fursultiamine hydrochloride, vitamin B 6 such, and vitamin B 12 compound, a solid preparation containing the calcium pantothenate, calcium pantothenate, calcium pantothenate, it to itself not neutral A solid preparation characterized by containing a basic magnesium or calcium lactate or carbonate in the presence of water and / or a lower alcohol and then drying the mixture. ,
(2) The solid preparation according to (1) above, containing vitamin B 12 as a granule obtained by spraying and drying an aqueous solution or aqueous dispersion thereof on a drug and / or excipient other than calcium pantothenate,
(3) The solid preparation according to (1), which is coated,
(4) By mixing calcium pantothenate with a neutral or basic magnesium or calcium lactate or carbonate in the presence of water and / or a lower alcohol, and then drying the mixture. The composition obtained is blended in a dry manner with granules obtained by spraying and drying an aqueous solution or aqueous dispersion of vitamin B 12 to drugs and / or excipients other than calcium pantothenate. And (5) calcium pantothenate and neutral or basic magnesium or calcium lactate or carbonate, water and / or lower alcohol a composition obtained by mixing in the presence of, and then drying the mixture, vitamin B 12 compound, an aqueous solution thereof or Spraying the dispersion in drug and / or excipients other than calcium pantothenate, and grain obtained by drying and fursultiamine hydrochloride, characterized by mixing a dry and a vitamin B 6, vitamin B The present invention provides a method for stabilizing both vitamin B 12 and calcium pantothenate in a solid preparation containing 12 and calcium pantothenate.
本発明によれば、パントテン酸カルシウムをパントテン酸カルシウム含有組成物の形態で、また、ビタミンB12類を所定の乾燥粒状形態で用いることにより、塩酸フルスルチアミン、ビタミンB6類、ビタミンB12類およびパントテン酸カルシウムを含有する固形のビタミン製剤であって、パントテン酸カルシウムおよびビタミンB12類が共に安定化された固形製剤を提供することができる。 According to the present invention, by using calcium pantothenate in the form of a calcium pantothenate-containing composition and vitamin B 12 in a predetermined dry granular form, fursultiamine hydrochloride, vitamin B 6 and vitamin B 12 are used. a vitamin preparations of solid containing class and calcium pantothenate can provide a solid preparation calcium pantothenate and vitamin B 12 compounds are both stabilized.
本発明で用いる塩酸フルスルチアミン、ビタミンB6類、ビタミンB12類およびパントテン酸カルシウムはビタミン製剤に通常用いられるものでよく、その量も特に限定するものではなく、通常のビタミン製剤におけると同様な量を用いることができる。
例えば、本発明で配合できるビタミンB6類としては、塩酸ピリドキシン、リン酸ピリドキサール等が挙げられる。ビタミンB12類としては、シアノコバラミン、塩酸ヒドロキソコバラミン、酢酸ヒドロキソコバラミン、メコバラミンが挙げられる。
Fursultiamine hydrochloride used in the present invention, vitamin B 6, vitamin B 12 acids and calcium pantothenate may be those commonly used in vitamin preparations, similarly if its amount is also not limited particularly, definitive normal vitamin preparations Various amounts can be used.
For example, vitamin B 6 such that can be incorporated in the present invention, pyridoxine hydrochloride, pyridoxal phosphate and the like. The vitamin B 12 compound, cyanocobalamin, hydrochloric hydroxocobalamin acetate hydroxocobalamin include mecobalamin.
本発明で用いられるパントテン酸カルシウム含有組成物は、上記特許第2891744号明細書に記載されており、当該明細書に記載の方法に従って製造できるが、具体的には、パントテン酸カルシウムと、それ自体が中性ないし塩基性のマグネシウムまたはカルシウムの乳酸塩または炭酸塩とを水および/または低級アルコールの存在下に混合し、ついで該混合物を乾燥することにより得られる。好ましくは、パントテン酸カルシウムと乳酸カルシウムとを水存在下に混合し、ついで該混合物を乾燥することにより得られる組成物である。また該組成物は市販品としても入手可能である(商品名パントテン酸カルシウムタイプS、BASF武田ビタミン)。 The calcium pantothenate-containing composition used in the present invention is described in the above-mentioned Japanese Patent No. 2891744 and can be produced according to the method described in the specification. Can be obtained by mixing neutral or basic magnesium or calcium lactate or carbonate in the presence of water and / or lower alcohol, and then drying the mixture. Preferably, the composition is obtained by mixing calcium pantothenate and calcium lactate in the presence of water, and then drying the mixture. The composition is also available as a commercial product (trade name: calcium pantothenate type S, BASF Takeda vitamin).
本発明においては、必要に応じて、上記以外のビタミン類、例えば、ビタミンB2類(リボフラビン、リン酸リボフラビン、酪酸リボフラビン等)、ビタミンE類(コハク酸dl−α―トコフェロールカルシウム、コハク酸d−α―トコフェロール、酢酸d−α―トコフェロール等)、ニコチン酸、ニコチン酸アミド、ガンマーオリザノール、オロチン酸、グルクロノラクトン、グルクロン酸アミド、ヨクイニン、ヘスペリジン、ビオチン、ビタミンC類(アスコルビン酸、アスコルビン酸カルシウム、アスコルビン酸ナトリウム等)、L−システイン、コンドロイチン硫酸ナトリウム等を配合してもよい。 In the present invention, vitamins other than the above, for example, vitamin B 2 (riboflavin, riboflavin phosphate, riboflavin butyrate, etc.), vitamin E (dl-α-tocopherol calcium succinate, succinate d) are used as necessary. -Α-tocopherol, acetic acid d-α-tocopherol, etc.), nicotinic acid, nicotinamide, gamma-oryzanol, orotic acid, glucuronolactone, glucuronic acid amide, yocuinine, hesperidin, biotin, vitamin C (ascorbic acid, ascorbic acid) Calcium, sodium ascorbate, etc.), L-cysteine, sodium chondroitin sulfate, etc. may be blended.
本発明において、ビタミンB12類の水溶液または水分散液を噴霧する薬物としては、塩酸フルスルチアミン、ビタミンB6類(塩酸ピリドキシン、リン酸ピリドキサール)、ビタミンB2類(リボフラビン、リン酸リボフラビン、酪酸リボフラビン等)、ビタミンE類(コハク酸dl−α―トコフェロールカルシウム、コハク酸d−α―トコフェロール、酢酸d−α―トコフェロール等)、ニコチン酸、ニコチン酸アミド、ガンマーオリザノール、オロチン酸、グルクロノラクトン、グルクロン酸アミド、ヨクイニン、ヘスペリジン、ビオチン、ビタミンC類(アスコルビン酸、アスコルビン酸カルシウム、アスコルビン酸ナトリウム等)、L−システイン、コンドロイチン硫酸ナトリウム等が挙げられる。特に好ましくは、塩酸フルスルチアミン、コンドロイチン硫酸ナトリウムである。
本発明において、ビタミンB12類の水溶液または水分散液を噴霧する賦形剤としては、部分α化デンプン、コーンスターチ、コムギデンプン、コメデンプン、バレイショデンプン、結晶セルロース、粉末セルロース、低置換度ヒドロキシプロピルセルロース、カルメロースカルシウム、カルメロースナトリウム、クロスカルメロースナトリウム、カルボキシメチルエチルセルロース、カルメロース、乳糖、マンニトール、エリスリトール、粉末還元麦芽糖水アメ、マルチトール、キシリトール、ソルビトール、トレハトース、ブドウ糖、塩酸グルコサミン、タルク、沈降炭酸カルシウム、リン酸水素カルシウム、無水リン酸水素カルシウム等が挙げられる。特に好ましくは、部分α化デンプン、結晶セルロース、粉末還元麦芽糖水アメである。
本発明においては、ビタミンB12類の水溶液または水分散液に、結合剤として、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、ヒドロキシエチルセルロース、プルラン、アラビアゴム末、デキストリン、ポリビニルピロリドン、ポリビニルアルコール、コポリビドン等を溶解または懸濁させてもよい。
In the present invention, as the drug for spraying an aqueous solution or dispersion of vitamin B 12 compound, fursultiamine hydrochloride, vitamin B 6 compound (pyridoxine hydrochloride, pyridoxal phosphate), vitamin B 2 compounds (riboflavin, riboflavin phosphate, Riboflavin butyrate), vitamin E (dl-α-tocopherol calcium succinate, d-α-tocopherol succinate, d-α-tocopherol acetate, etc.), nicotinic acid, nicotinamide, gamma-oryzanol, orotic acid, glucurono Examples thereof include lactone, glucuronic acid amide, yocuinine, hesperidin, biotin, vitamin Cs (ascorbic acid, calcium ascorbate, sodium ascorbate, etc.), L-cysteine, sodium chondroitin sulfate and the like. Particularly preferred are fursultiamine hydrochloride and sodium chondroitin sulfate.
In the present invention, excipients spraying an aqueous solution or dispersion of vitamin B 12 compound, partially α-starch, corn starch, wheat starch, rice starch, potato starch, crystalline cellulose, powdered cellulose, low substituted hydroxypropylcellulose Cellulose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl ethyl cellulose, carmellose, lactose, mannitol, erythritol, powdered reduced maltose water candy, maltitol, xylitol, sorbitol, trehatose, glucose, glucosamine hydrochloride, talc, sedimentation Examples thereof include calcium carbonate, calcium hydrogen phosphate, and anhydrous calcium hydrogen phosphate. Particularly preferred are partially pregelatinized starch, crystalline cellulose, and powdered reduced maltose water candy.
In the present invention, the aqueous solution or dispersion of vitamin B 12 compounds, as binder, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, hydroxyethyl cellulose, pullulan, gum arabic powder, dextrin, polyvinyl pyrrolidone, polyvinyl alcohol, copolyvidone, etc. May be dissolved or suspended.
本発明においては、ビタミンB12類は、かかるビタミンB12類の適宜の濃度の水溶液または水分散液を、常法に従って、薬物および/または賦形剤に噴霧、乾燥して得られた粒として固形製剤に含有させる。
このような粒には、さらにコーティング剤を用い、常法によりコーティングしてもよい。該コーティング剤としては、例えば、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、エチルセルロース、プルラン、アラビアゴム末、ポリビニルピロリドン、ポリビニルアルコール、コポリビドン、ポリビニルアセタールジエチルアミノアセテート、メタアクリル酸コポリマーL、メタアクリル酸コポリマーLD、メタアクリル酸コポリマーS、アミノアルキルメタアクリレートコポリマーE、アミノアルキルメタアクリレートコポリマーRS、マクロゴール6000、ヒドロキシプロピルメチルセルロースフタレート、ヒドロキシプロピルメチルセルロースアセテートサクシネート等が挙げられる。
In the present invention, vitamin B 12 is a granule obtained by spraying and drying an aqueous solution or aqueous dispersion of an appropriate concentration of such vitamin B 12 on a drug and / or excipient according to a conventional method. Included in solid formulation.
Such particles may be coated by a conventional method using a coating agent. Examples of the coating agent include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, pullulan, gum arabic powder, polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, polyvinyl acetal diethylaminoacetate, methacrylic acid copolymer L, methacrylic acid copolymer LD. , Methacrylic acid copolymer S, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, macrogol 6000, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, and the like.
本発明の固形製剤は、例えば、顆粒剤、細粒剤、素錠、フィルム錠、薄層糖衣錠、糖衣錠、チユアブル錠等の剤形とすることができ、必要に応じて、さらに上記以外の固形製剤に通常使用される成分を含有させてもよい。 The solid preparation of the present invention can be made into dosage forms such as granules, fine granules, uncoated tablets, film tablets, thin-layer sugar-coated tablets, sugar-coated tablets, and chewable tablets. You may make it contain the component normally used for a formulation.
本発明の固形製剤は、例えば、造粒ハンドブック(日本粉体工業技術協会編、オーム社)、経口投与製剤の処方設計(京都大学大学院薬学研究科教授 橋田充編、薬業時報社)、粉体の圧縮成形技術(粉体工学・製剤と粒子設計部会編、日刊工業新聞社)のような刊行物に記載されている一般的な方法で製造することができる。
特に、本発明においては、上記のパントテン酸カルシウム含有組成物と、ビタミンB12類の粒を乾式で配合することが好ましい。これは、例えば、ビタミンB12類の粒を造粒した後、得られた整粒末にパントテン酸カルシウム含有組成物を混合することにより実施できる。ついで、この混合物を乾燥状態のまま、固形製剤とすればよい。
The solid preparation of the present invention includes, for example, a granulation handbook (edited by Japan Powder Industrial Technology Association, Ohm Co., Ltd.), a prescription design for an orally administered preparation (Professor Mitsuru Hashida, Graduate School of Pharmaceutical Sciences, Kyoto University), powder It can be produced by a general method described in publications such as body compression molding technology (powder engineering / preparation and particle design division, edited by Nikkan Kogyo Shimbun).
Particularly, in the present invention, it is preferred to blend the above calcium pantothenate-containing composition, a particle of vitamin B 12 compound in dry. This can be carried out, for example, by granulating vitamin B 12 grains and then mixing the obtained sized powder with a calcium pantothenate-containing composition. Then, the mixture may be made into a solid preparation while still in a dry state.
さらに、塩酸フルスルチアミンが不快なにおいと味をもつため、本発明においては、そのマスキングのために固形製剤をコーティングすることが好ましく、これにより、服用性に優れた固形製剤が得られる。本発明におけるコーティングとしては、フィルムコーティング、糖衣等があり、特に制限はないが、本発明者らが発明した薄層糖衣(特開2002−179559号公報)を施すことが好ましい。薄層糖衣に用いる糖質、賦形剤、結合剤には特に制限はない。薄層糖衣としては、アンダーコーティング(UC)、ビルドアップコーティング(BC)、シロップコーティング(SC)の3層を施すことが好ましい。UCとしては、ヒドロキシプロピルメチルセルロース等の水溶性高分子、タルク等の賦形剤等を、BCとしては、エリスリトール等の糖質、タルク、沈降炭酸カルシウム等の賦形剤剤、アラビゴム末、結晶セルロース等の結合剤等を、SCとしては、エリスリトール等の糖質、リボフラビン等の着色剤を配合するのが好ましい。この際、エリスリトールに他の糖質、例えばショ糖(精製白糖、白糖)、トレハロース、マルチトール、粉末還元麦芽糖水アメ、マンニトール、ソルビトール、キシリトール、乳糖等を1種以上組み合わせてもよい。
以下に実施例を挙げて本発明をさらに詳しく説明するが、本発明はこれらに限定されるものではない。
Furthermore, since fursultiamine hydrochloride has an unpleasant odor and taste, in the present invention, it is preferable to coat a solid preparation for masking, thereby obtaining a solid preparation excellent in dosing. The coating in the present invention includes film coating, sugar coating and the like, and is not particularly limited. However, it is preferable to apply a thin layer sugar coating (Japanese Patent Laid-Open No. 2002-179559) invented by the present inventors. There is no restriction | limiting in particular in the saccharide | sugar, excipient | filler, and binder which are used for thin layer sugar coating. As the thin layer sugar coating, it is preferable to apply three layers of undercoating (UC), build-up coating (BC), and syrup coating (SC). As UC, water-soluble polymers such as hydroxypropylmethylcellulose, excipients such as talc, etc., and as BC, carbohydrates such as erythritol, talc, excipients such as precipitated calcium carbonate, arabi rubber powder, crystalline cellulose As the SC, a binder such as erythritol and a coloring agent such as riboflavin are preferably added as SC. At this time, other sugars such as sucrose (purified sucrose, sucrose), trehalose, maltitol, powdered reduced maltose syrup, mannitol, sorbitol, xylitol, lactose and the like may be combined with erythritol.
The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto.
塩酸フルスルチアミン1142g、リボフラビン118.8g、塩酸ピリドキシン200g、乳糖1950g、コーンスターチ439.2gにヒドロキシプロピルセルロース(HPC−L)170gを精製水2660gに溶解させた水溶液を流動層造粒機(FD−5S、パウレック)にて噴霧し、造粒した。得られた造粒末を整粒機(パワーミル、昭和機械化工)にて整粒し、整粒末を得た。部分アルファー化デンプン1797g、コーンスターチ1.079gにシアノコバラミン1.921gを精製水708gに溶解させた水溶液を流動層造粒機(FD−5S、パウレック)にて噴霧し、シアノコバラミン吸着末を得た。続いて、ヒドロキシプロピルメチルセルロース(TC−5MW)180gを精製水1320gに溶解させた水溶液を流動層造粒機(FD−5S、パウレック)にて噴霧し、シアノコバラミンコーティング粒を得た。得られたコーティング粒は整粒機(パワーミル、昭和化学機械)にて整粒した。
整粒末3216g、整粒したシアノコバラミンコーティング粒528g、パントテン酸カルシウムタイプS189.4g、結晶セルロース(旭化成品PH101)240g、コーンスターチ125g、ステアリン酸マグネシウム21.6gを混合機(タンブラー混合機(15L)、昭和化学機械)にて混合し、混合末を得た。得られた混合末をロータリー式打錠機(コレクト12HUK、菊水製作所)にて、直径8mmの臼と曲率半径9mm、3mmの2段Rをもつ杵を用い、重量180mg、厚み3.90mmの素錠を得た。
得られた素錠3240gをコーティング機(ドリアコーターDRC−500、パウレック)に仕込み、ヒドロキシプロピルメチルセルロース(TC−5MW)108g、タルク12gを精製水1080gに溶解、懸濁させたコーティング液を素錠に噴霧し、1錠あたり4mgコーティングし、アンダーコーティング(UC)錠を得た。続いて、UC錠に、エリスリトール1003g、タルク189.2g、沈降炭酸カルシウム340.6g、酸化チタン37.85g、結晶セルロース(アビセルPH−F20)94.62g、アラビアゴム末227.1gを精製水2839gに溶解、懸濁させたコーティング液を噴霧し、1錠あたり76mgコーティングし、ビルドアップコーティング(BC)錠を得た。続いてBC錠に、精製白糖418.8g、エリスリトール179.5g、リボフラビン1.707gを精製水300.9gに溶解、懸濁させたコーティング液を用い、1錠あたり20mgコーティングし、シロップコーティング(SC)錠を得た。SC錠に、カルナウバロウ、セラックパール、ヒマシ油、エタノール、n−ヘキサンを溶解させた艶出液を注液、乾燥し、艶出した薄層糖衣錠を得た。
Fluidized bed granulator (FD-) prepared by dissolving 1142 g of fursultiamine hydrochloride, 118.8 g of riboflavin, 200 g of pyridoxine hydrochloride, 1950 g of lactose, 439.2 g of corn starch and 170 g of hydroxypropylcellulose (HPC-L) in 2660 g of purified water. 5S, Paulek) and granulated. The obtained granulated powder was sized with a sizing machine (Power Mill, Showa Mechanics) to obtain a sized powder. An aqueous solution in which 1.921 g of cyanocobalamin was dissolved in 708 g of purified water in 1797 g of partially pregelatinized starch and 1.079 g of corn starch was sprayed with a fluidized bed granulator (FD-5S, Paulek) to obtain a cyanocobalamin adsorption powder. Subsequently, an aqueous solution in which 180 g of hydroxypropylmethylcellulose (TC-5MW) was dissolved in 1320 g of purified water was sprayed with a fluidized bed granulator (FD-5S, Powrec) to obtain cyanocobalamin coated granules. The obtained coated particles were sized using a sizing machine (Power Mill, Showa Chemical Machinery).
3216g of sized powder, 528g of sized cyanocobalamin coated particles, calcium pantothenate type S189.4g, 240g of crystalline cellulose (Asahi Kasei PH101), 125g of corn starch, 21.6g of magnesium stearate (tumbler mixer (15L)), Mixed by Showa Chemical Machinery Co., Ltd.) to obtain a mixed powder. The resulting mixed powder was mixed with a rotary tableting machine (collect 12HUK, Kikusui Seisakusho) using a pestle having a diameter of 8 mm, a radius of curvature of 9 mm, and a radius of 2 mm, and a weight of 180 mg and a thickness of 3.90 mm. I got a tablet.
3240 g of the obtained uncoated tablet is charged into a coating machine (Dria Coater DRC-500, Paulek), and 108 g of hydroxypropylmethylcellulose (TC-5MW) and 12 g of talc are dissolved and suspended in 1080 g of purified water. Spraying and coating 4 mg per tablet gave undercoating (UC) tablets. Subsequently, 1003 g of erythritol, 189.2 g of talc, 340.6 g of precipitated calcium carbonate, 37.85 g of titanium oxide, 94.62 g of crystalline cellulose (Avicel PH-F20), 227.1 g of gum arabic powder, and 2839 g of purified gum powder were added to UC tablets. The coating solution dissolved and suspended in was sprayed, and 76 mg per tablet was coated to obtain build-up coating (BC) tablets. Subsequently, a BC tablet was coated with 20 mg per tablet using a coating solution in which 418.8 g of purified white sugar, 179.5 g of erythritol and 1.707 g of riboflavin were dissolved and suspended in 300.9 g of purified water, and syrup coating (SC ) I got a tablet. A glaze solution in which carnauba wax, shellac pearl, castor oil, ethanol, and n-hexane were dissolved in SC tablets was poured and dried to obtain a glaze thin-layer sugar-coated tablet.
塩酸フルスルチアミン 2883g、結晶セルロース(旭化成品PH101)714.5gにシアノコバラミン40gを精製水3000gに溶解させた水溶液を流動層造粒機(FD−5S、パウレック)にて噴霧した。その後、HPC−L112.5gを精製水1763gに溶解させた水溶液を流動層造粒機(FD−5S、パウレック)にて噴霧し、造粒した。得られた造粒末を整粒機(パワーミル、昭和機械化工)にて整粒し、T群整粒末を得た。コハク酸dl−α−トコフェロールカルシウム1544g、塩酸ピリドキシン1400g、ガンマーオリザノール143.1g、軽質無水ケイ酸(サイリシア320)216.3g、結晶セルロース(旭化成品KG802)554gにHPC−L203gを精製水3181gに溶解させた水溶液を流動層造粒機(FD−5S、パウレック)にて噴霧し、造粒した。得られた造粒末を整粒機(パワーミル、昭和化学機械)にて整粒し、E群整粒末を得た。
T群整粒末1800g、E群整粒末3480g、パントテン酸カルシウムタイプS562.7g、軽質無水ケイ酸(サイリシア320)66.6g、結晶セルロース(旭化成品KG802)354.7g、L−HPC(LH31)336g、ステアリン酸マグネシウム60gを混合機(タンブラー混合機(60L)、昭和化学機械)にて混合し、混合末を得た。得られた混合末をロータリー式打錠機(コレクト12HUK、菊水製作所)にて直径8.3mmの臼と曲率半径9.3mm、3.1mmの2段Rをもつ杵を用い、重量185mg、厚み4.11mmの素錠を得た。
得られた素錠3330gをコーティング機(ドリアコーターDRC−500、パウレック)に仕込み、ヒドロキシプロピルメチルセルロース(TC−5MW)129.6g、タルク14.4gを精製水1152gに溶解、懸濁させたコーティング液を素錠に噴霧し、1錠あたり4mgコーティングし、アンダーコーティング(UC)錠を得た。続いて、UC錠に、エリスリトール1082g、タルク204.1g、沈降炭酸カルシウム367.4g、酸化チタン40.82g、結晶セルロース(アビセルPH−F20)102.1g、アラビアゴム末244.9gを精製水3062gに溶解、懸濁させたコーティング液を噴霧し、1錠あたり81mgコーティングし、ビルドアップコーティング(BC)錠を得た。続いてBC錠に、精製白糖351.8g、エリスリトール150.8g、リボフラビン1.428gを精製水252.8gに溶解、懸濁させたコーティング液を用い、1錠あたり20mgコーティングし、シロップコーティング(SC)錠を得た。SC錠に、カルナウバロウ、セラックパール、ヒマシ油、エタノール、n−ヘキサンを溶解させた艶出液を注液、乾燥し、艶出した薄層糖衣錠を得た。
An aqueous solution prepared by dissolving 28 g of fursultiamine hydrochloride and 714.5 g of crystalline cellulose (Asahi Kasei PH101) in 40 g of cyanocobalamin in 3000 g of purified water was sprayed with a fluidized bed granulator (FD-5S, Powrec). Thereafter, an aqueous solution in which 112.5 g of HPC-L was dissolved in 1763 g of purified water was sprayed and granulated with a fluidized bed granulator (FD-5S, Powrec). The obtained granulated powder was sized with a sizing machine (Power Mill, Showa Mechanics) to obtain a T group sized powder. Dissolve HPC-L203g in purified water 3181g in 1544g succinic acid dl-α-tocopherol calcium 1544g, pyridoxine hydrochloride 1400g, gamma-oryzanol 143.1g, light anhydrous silicic acid (Silysia 320) 216.3g, crystalline cellulose (Asahi Kasei KG802) 554g The aqueous solution was sprayed and granulated with a fluidized bed granulator (FD-5S, Powrec). The obtained granulated powder was sized using a sizing machine (Power Mill, Showa Chemical Machinery) to obtain Group E sized powder.
Group T sized powder 1800 g, Group E sized powder 3480 g, calcium pantothenate type S562.7 g, light anhydrous silicic acid (Silysia 320) 66.6 g, crystalline cellulose (Asahi Kasei KG802) 354.7 g, L-HPC (LH31) 336 g and magnesium stearate 60 g were mixed in a mixer (tumbler mixer (60 L), Showa Chemical Machinery) to obtain a mixed powder. The obtained mixed powder was rotograted with a rotary tableting machine (collect 12HUK, Kikusui Seisakusho) using a 8.3 mm diameter mortar and a radius of 9.3 mm and a radius of 3.1 mm and a two-stage radius R, weight 185 mg, thickness A 4.11 mm uncoated tablet was obtained.
A coating solution in which 3330 g of the resulting uncoated tablet was charged into a coating machine (Dria Coater DRC-500, Paulek), and 129.6 g of hydroxypropylmethylcellulose (TC-5MW) and 14.4 g of talc were dissolved and suspended in 1152 g of purified water. Was sprayed onto the uncoated tablets and coated with 4 mg per tablet to obtain undercoating (UC) tablets. Subsequently, 1082 g of erythritol, 204.1 g of talc, 367.4 g of precipitated calcium carbonate, 40.82 g of titanium oxide, 102.1 g of crystalline cellulose (Avicel PH-F20), 244.9 g of gum arabic powder and 3062 g of purified water powder were added to the UC tablet. The coating solution dissolved and suspended in was sprayed and coated with 81 mg per tablet to obtain build-up coating (BC) tablets. Subsequently, 35 mg of purified white sugar, 150.8 g of erythritol, and 1.428 g of riboflavin were dissolved and suspended in 252.8 g of purified water on BC tablets, and 20 mg per tablet was coated with syrup coating (SC ) I got a tablet. A glaze solution in which carnauba wax, shellac pearl, castor oil, ethanol, and n-hexane were dissolved in SC tablets was poured and dried to obtain a glaze thin-layer sugar-coated tablet.
塩酸フルスルチアミン545.8g、リボフラビン59.27g、塩酸ピリドキシン100g、乳糖1222.63g、結晶セルロース(アビセルPH101)340gにシアノコバラミン0.3gを精製水100gに溶解させた水溶液を流動層造粒機(FD−3SN、パウレック)にて噴霧し、続いてHPC−L70gを精製水1097gに溶解させた水溶液を噴霧し、造粒した。得られた造粒末を整粒機(パワーミル、昭和機械化工)にて整粒し、整粒末を得た。
整粒末1870.4g、パントテン酸カルシウムタイプS61.6g、結晶セルロース(旭化成品PH101)120g、低置換度ヒドロキシプロピルセルロース(L−HPC)(LH31)98g、ステアリン酸マグネシウム10gを混合機(タンブラー混合機(15L)、昭和化学機械)にて混合し、混合末を得た。得られた混合末をロータリー式打錠機(コレクト19AWC、菊水製作所)にて、直径8mmの臼と曲率半径9mm、3mmの2段Rをもつ杵を用い、重量180mg、厚み3.90mmの素錠を得た。
得られた素錠300gをコーティング機(ハイコーターMINI、フロイント)に仕込み、エリスリトール530g、タルク100g、沈降炭酸カルシウム180g、酸化チタン20g、結晶セルロース(アビセルPH−F20)50g、アラビアゴム末120gを精製水1632gに溶解、懸濁させたコーティング液を噴霧し、1錠あたり60mgコーティングした。続いて、精製白糖530g、タルク170g、沈降炭酸カルシウム170g、酸化チタン20g、アラビアゴム末60g、PEG6000 50gを精製水1632gに溶解、懸濁させたコーティング液を噴霧し、1錠あたり20mgコーティングし、ビルドアップコーティング(BC)錠を得た。続いてBC錠に、精製白糖748.3g、リボフラビン1.7gを精製水374.3gに溶解、懸濁させたコーティング液を用い、1錠あたり20mgコーティングし、シロップコーティング(SC)錠を得た。SC錠に、カルナウバロウ、セラックパール、ヒマシ油、エタノール、n−ヘキサンを溶解させた艶出液を注液、乾燥し、艶出した薄層糖衣錠を得た。
Fluidized bed granulator with an aqueous solution prepared by dissolving 0.35.8 g of cyanocobalamin in 100 g of purified water in 545.8 g of fursultiamine hydrochloride, 59.27 g of riboflavin, 100 g of pyridoxine hydrochloride, 122.63 g of lactose and 340 g of crystalline cellulose (Avicel PH101) ( (FD-3SN, Paulek), followed by spraying and granulating an aqueous solution in which 70 g of HPC-L was dissolved in 1097 g of purified water. The obtained granulated powder was sized with a sizing machine (Power Mill, Showa Mechanics) to obtain a sized powder.
Mixing machine (tumbler mixing) 1870.4g of sized powder, 61.6g of calcium pantothenate type, 120g of crystalline cellulose (Asahi Kasei PH101), 98g of low substituted hydroxypropyl cellulose (L-HPC) (LH31), 10g of magnesium stearate (15L), Showa Chemical Machinery Co., Ltd.) to obtain a mixed powder. The resulting mixed powder was mixed with a rotary tableting machine (collect 19AWC, Kikusui Seisakusho) using a pestle having a diameter of 8 mm, a radius of curvature of 9 mm, and a radius of 3 mm and a two-step radius of 180 mg and a thickness of 3.90 mm. I got a tablet.
300 g of the obtained uncoated tablet was charged into a coating machine (Hicoater MINI, Freund), and erythritol 530 g, talc 100 g, precipitated calcium carbonate 180 g, titanium oxide 20 g, crystalline cellulose (Avicel PH-F20) 50 g, and gum arabic powder 120 g were purified. A coating solution dissolved and suspended in 1632 g of water was sprayed to coat 60 mg per tablet. Subsequently, 530 g of purified sucrose, 170 g of talc, 170 g of precipitated calcium carbonate, 20 g of titanium oxide, 60 g of gum arabic powder, 50 g of PEG 6000 were dissolved in 1632 g of purified water and sprayed with a coating solution, and 20 mg per tablet was coated. Build-up coating (BC) tablets were obtained. Subsequently, 20 mg per tablet was coated on BC tablets using a coating solution obtained by dissolving and suspending 748.3 g of purified white sugar and 1.7 g of riboflavin in 374.3 g of purified water to obtain syrup-coated (SC) tablets. . A glaze solution in which carnauba wax, shellac pearl, castor oil, ethanol, and n-hexane were dissolved in SC tablets was poured and dried to obtain a glaze thin-layer sugar-coated tablet.
比較例1
塩酸フルスルチアミン545.8g、リボフラビン59.27g、塩酸ピリドキシン100g、パントテン酸カルシウム結晶50g、乳糖1249.63g、結晶セルロース(旭化成品PH101)340gにシアノコバラミン0.3gを精製水100gに溶解させた水溶液を流動層造粒機(FD−3SN、パウレック)にて噴霧し、続いてHPC−L70gを精製水1097gに溶解させた水溶液を噴霧し、造粒した。得られた造粒末を整粒機(パワーミル、昭和機械化工)にて整粒し、整粒末を得た。
整粒末1932g、結晶セルロース(旭化成品PH101)120g、低置換度ヒドロキシプロピルセルロース(L−HPC)(LH31)98g、ステアリン酸マグネシウム10gを混合機(タンブラー混合機(15L)、昭和化学機械)にて混合し、混合末を得た。得られた混合末をロータリー式打錠機(コレクト19AWC、菊水製作所)にて、直径8mmの臼と曲率半径9mm、3mmの2段Rをもつ杵を用い、重量180mg、厚み3.90mmの素錠を得た。
得られた素錠を実施例3と同じ操作で、コーティングし、艶出された薄層糖衣錠を得た。
Comparative Example 1
An aqueous solution in which 0.3g of cyanocobalamin was dissolved in 100g of purified water in 545.8g of fursultiamine hydrochloride, 59.27g of riboflavin, 100g of pyridoxine hydrochloride, 50g of calcium pantothenate crystals, 1249.63g of lactose, and 340g of crystalline cellulose (Asahi Kasei PH101). Was sprayed with a fluidized bed granulator (FD-3SN, Paulek), and then an aqueous solution in which 70 g of HPC-L was dissolved in 1097 g of purified water was sprayed and granulated. The obtained granulated powder was sized with a sizing machine (Power Mill, Showa Mechanics) to obtain a sized powder.
In a blender (tumbler blender (15L), Showa Kagaku Kikai) 1932g of sized powder, 120g of crystalline cellulose (Asahi Kasei PH101), 98g of low substituted hydroxypropylcellulose (L-HPC) (LH31), 10g of magnesium stearate And mixed to obtain a mixed powder. The resulting mixed powder was mixed with a rotary tableting machine (collect 19AWC, Kikusui Seisakusho) using a pestle having a diameter of 8 mm, a radius of curvature of 9 mm, and a radius of 3 mm and a two-step radius of 180 mg and a thickness of 3.90 mm. I got a tablet.
The obtained uncoated tablet was coated by the same operation as in Example 3 to obtain a glazed thin-layer sugar-coated tablet.
試験例1
薄層糖衣錠中のシアノコバラミンおよびパントテン酸カルシウム含量安定性
平衡相対湿度(ERH)40%以下に低水分化された実施例1、実施例2、実施例3、比較例1の薄層糖衣錠を40℃1ケ月ガラス瓶密栓保存し、シアノコバラミンおよびパントテン酸カルシウム含量の残存率を測定した。
結果を表1に示す。
Stability of cyanocobalamin and calcium pantothenate content in thin-layer sugar-coated tablets The thin-layer sugar-coated tablets of Example 1, Example 2, Example 3, and Comparative Example 1 that had been reduced in water to an equilibrium relative humidity (ERH) of 40% or less were 40 ° C. The glass bottle was sealed for 1 month and the residual ratio of cyanocobalamin and calcium pantothenate content was measured.
The results are shown in Table 1.
実施例2におけるシアノコバラミン40gを溶解させる精製水を1000gにし、精製水にシアノコバラミンを分散させた懸濁液を用い、その後は、実施例2と同じ操作で薄層糖衣錠を得た。 The purified water in which 40 g of cyanocobalamin in Example 2 was dissolved was changed to 1000 g, and a suspension in which cyanocobalamin was dispersed in purified water was used.
比較例2
実施例2におけるシアノコバラミン40gを粉末として流動層造粒機(FD−5S、パウレック)に仕込み、その後は、実施例2と同じに操作で薄層糖衣錠を得た。
Comparative Example 2
40 g of cyanocobalamin in Example 2 was charged into a fluidized bed granulator (FD-5S, Paulek) as a powder, and thereafter, a thin-layer sugar-coated tablet was obtained in the same manner as in Example 2.
試験例2
薄層糖衣錠中のシアノコバラミン含量安定性
平衡相対湿度(ERH)40%以下に低水分化された実施例2、実施例4、比較例2の薄層糖衣錠を60℃4週間ガラス瓶密栓保存し、シアノコバラミン含量の残存率を測定した。
結果を表2に示す。
Stability of cyanocobalamin content in thin-layer sugar-coated tablets The thin-layer sugar-coated tablets of Examples 2, 4 and Comparative Example 2 whose moisture content was reduced to an equilibrium relative humidity (ERH) of 40% or less were stored in glass bottles sealed at 60 ° C. for 4 weeks, and cyanocobalamin was stored. The residual rate of content was measured.
The results are shown in Table 2.
以上記載したごとく、本発明によれば、塩酸フルスルチアミン、ビタミンB6類、ビタミンB12類およびパントテン酸カルシウムを含有する固形のビタミン製剤であって、パントテン酸カルシウムおよびビタミンB12類が共に安定化された固形製剤を提供することができる。 As described above, according to the present invention, fursultiamine hydrochloride, vitamin B 6 such, a vitamin formulation solids containing vitamin B 12 acids and calcium pantothenate, calcium pantothenate and vitamin B 12 compounds are both A stabilized solid formulation can be provided.
Claims (3)
パントテン酸カルシウムを、パントテン酸カルシウムと、それ自体が中性ないし塩基性のマグネシウムまたはカルシウムの乳酸塩または炭酸塩とを、水および/または低級アルコールの存在下に混合し、ついで該混合物を乾燥することにより得られる組成物として含有すること;および
ビタミンB12類を、その水溶液または水分散液を賦形剤に噴霧、乾燥して得られた粒として含有すること;ここに、該賦形剤が、部分α化デンプン、コーンスターチ、コムギデンプン、コメデンプン、バレイショデンプン、結晶セルロース、粉末セルロース、低置換度ヒドロキシプロピルセルロース、カルメロースカルシウム、カルメロースナトリウム、クロスカルメロースナトリウム、カルボキシメチルエチルセルロース、およびカルメロースから選択される1種またはそれ以上のものである;
を特徴とする固形製剤。 And fursultiamine hydrochloride, vitamin B 6 such, and vitamin B 12 compound, a solid preparation containing the calcium pantothenate,
Calcium pantothenate is mixed with calcium pantothenate and itself a neutral or basic magnesium or calcium lactate or carbonate in the presence of water and / or a lower alcohol, and then the mixture is dried. Containing vitamin B 12 as granules obtained by spraying an aqueous solution or aqueous dispersion thereof onto an excipient and drying; and Is partially pregelatinized starch, corn starch, wheat starch, rice starch, potato starch, crystalline cellulose, powdered cellulose, low-substituted hydroxypropylcellulose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethylethylcellulose, and carmellose Select from Is is one or more of those;
A solid preparation characterized by
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011112646A JP5524130B2 (en) | 2011-05-19 | 2011-05-19 | Stabilized vitamin preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011112646A JP5524130B2 (en) | 2011-05-19 | 2011-05-19 | Stabilized vitamin preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004297597A Division JP4841130B2 (en) | 2004-10-12 | 2004-10-12 | Stabilized vitamin preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011162561A JP2011162561A (en) | 2011-08-25 |
JP5524130B2 true JP5524130B2 (en) | 2014-06-18 |
Family
ID=44593653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011112646A Expired - Lifetime JP5524130B2 (en) | 2011-05-19 | 2011-05-19 | Stabilized vitamin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5524130B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778979A (en) * | 2015-10-07 | 2023-03-14 | 帝斯曼知识产权资产管理有限公司 | Multivitamin extrudates |
CN111093667A (en) * | 2017-07-11 | 2020-05-01 | 武田消费保健株式会社 | Solid preparation containing vitamin B1 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2689458B2 (en) * | 1988-02-09 | 1997-12-10 | 武田薬品工業株式会社 | Granular or powdered Vitamin B composition containing lower 1 and lower 2 |
HU208626B (en) * | 1989-04-19 | 1993-12-28 | Takeda Chemical Industries Ltd | Process for producing stabile compositions containing calcium-pantothenate |
DK0416773T3 (en) * | 1989-08-31 | 1993-03-29 | Takeda Chemical Industries Ltd | Vitamin B12 preparation |
JPH09124480A (en) * | 1995-10-27 | 1997-05-13 | Takeda Chem Ind Ltd | Vitamin preparation |
JP2000016940A (en) * | 1998-04-28 | 2000-01-18 | Takeda Chem Ind Ltd | Composition containing vitamins b12 |
JP2003128543A (en) * | 2001-10-23 | 2003-05-08 | Takeda Chem Ind Ltd | Solid pharmaceutical preparation containing ascorbic acid or its salt and calcium pantothenate, and method for producing the same |
JP4427318B2 (en) * | 2002-02-07 | 2010-03-03 | 武田薬品工業株式会社 | Film coated tablets |
JP4841130B2 (en) * | 2004-10-12 | 2011-12-21 | 武田薬品工業株式会社 | Stabilized vitamin preparation |
-
2011
- 2011-05-19 JP JP2011112646A patent/JP5524130B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2011162561A (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4984455B2 (en) | Double coated tablets | |
EP2167046B1 (en) | Pharmaceutical solid preparation comprising benzazepines and production method thereof | |
EP2898899A1 (en) | Disintegrating particle composition containing acid-type carboxymethylcellulose and crystalline cellulose, and orally disintegrating tablet containing said composition | |
EP2854773B1 (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
JP5504312B2 (en) | Thin-layer sugar-coated tablet and method for producing the same | |
EP3257511B1 (en) | Orally disintegrating tablet and method for manufacturing same | |
JP2007197410A (en) | Film-coated tablet | |
JP4841130B2 (en) | Stabilized vitamin preparation | |
JP5524130B2 (en) | Stabilized vitamin preparation | |
WO2014193528A1 (en) | Amorphous dosage forms and methods | |
JP6393549B2 (en) | Vitamin B12-containing composition | |
JP2010024181A (en) | Solid preparation and method for producing the same | |
WO2012139736A1 (en) | Pharmaceutical composition comprising bosentan | |
JP5248733B2 (en) | Volatilization-preventing solid preparation and method for producing the same | |
JP2020111532A (en) | Solid preparation comprising vitamin b1 | |
WO2020021110A1 (en) | Pharmaceutical composition of ticagrelor | |
JP5198001B2 (en) | Stabilized solid formulation | |
JP2000016940A (en) | Composition containing vitamins b12 | |
JP5158922B2 (en) | Composition containing vitamin B12 | |
JPH09124480A (en) | Vitamin preparation | |
JP2003128543A (en) | Solid pharmaceutical preparation containing ascorbic acid or its salt and calcium pantothenate, and method for producing the same | |
WO2020111089A1 (en) | Pharmaceutical composition | |
TWI374759B (en) | Stabilized vitamine preparation | |
TWI507216B (en) | Stabilized vitamine preparation | |
JP4350704B2 (en) | Pharmaceutical additives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110519 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130812 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20130903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130917 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140401 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5524130 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
SG99 | Written request for registration of restore |
Free format text: JAPANESE INTERMEDIATE CODE: R316G99 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R316531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R316533 |
|
S803 | Written request for registration of cancellation of provisional registration |
Free format text: JAPANESE INTERMEDIATE CODE: R316803 |
|
SG99 | Written request for registration of restore |
Free format text: JAPANESE INTERMEDIATE CODE: R316G99 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |